The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.